TY - JOUR
T1 - Prime editing for functional repair in patient-derived disease models
AU - Schene, Imre F
AU - Joore, Indi P
AU - Oka, Rurika
AU - Mokry, Michal
AU - van Vugt, Anke H M
AU - van Boxtel, Ruben
AU - van der Doef, Hubert P J
AU - van der Laan, Luc J W
AU - Verstegen, Monique M A
AU - van Hasselt, Peter M
AU - Nieuwenhuis, Edward E S
AU - Fuchs, Sabine A
N1 - Funding Information:
The authors are grateful for the collaborative “United for Metabolic Diseases (UMD)” efforts to improve care for patients with (genetic) metabolic diseases. We thank M. Geurts (Hubrecht Institute, the Netherlands) for providing WNT surrogate and for sharing his experiences with prime editing. We thank Henkjan J. Verkade sharing unique patient-derived material. This work was supported by Metakids funding (to S.A.F.) and a Clinical Fellows grant from The Netherlands Organisation for Health Research and Development Health Institute (40-00703-97-13537 to S.A.F.).
Publisher Copyright:
© 2020, The Author(s).
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Prime editing is a recent genome editing technology using fusion proteins of Cas9-nickase and reverse transcriptase, that holds promise to correct the vast majority of genetic defects. Here, we develop prime editing for primary adult stem cells grown in organoid culture models. First, we generate precise in-frame deletions in the gene encoding β-catenin (CTNNB1) that result in proliferation independent of Wnt-stimuli, mimicking a mechanism of the development of liver cancer. Moreover, prime editing functionally recovers disease-causing mutations in intestinal organoids from patients with DGAT1-deficiency and liver organoids from a patient with Wilson disease (ATP7B). Prime editing is as efficient in 3D grown organoids as in 2D grown cell lines and offers greater precision than Cas9-mediated homology directed repair (HDR). Base editing remains more reliable than prime editing but is restricted to a subgroup of pathogenic mutations. Whole-genome sequencing of four prime-edited clonal organoid lines reveals absence of genome-wide off-target effects underscoring therapeutic potential of this versatile and precise gene editing strategy.
AB - Prime editing is a recent genome editing technology using fusion proteins of Cas9-nickase and reverse transcriptase, that holds promise to correct the vast majority of genetic defects. Here, we develop prime editing for primary adult stem cells grown in organoid culture models. First, we generate precise in-frame deletions in the gene encoding β-catenin (CTNNB1) that result in proliferation independent of Wnt-stimuli, mimicking a mechanism of the development of liver cancer. Moreover, prime editing functionally recovers disease-causing mutations in intestinal organoids from patients with DGAT1-deficiency and liver organoids from a patient with Wilson disease (ATP7B). Prime editing is as efficient in 3D grown organoids as in 2D grown cell lines and offers greater precision than Cas9-mediated homology directed repair (HDR). Base editing remains more reliable than prime editing but is restricted to a subgroup of pathogenic mutations. Whole-genome sequencing of four prime-edited clonal organoid lines reveals absence of genome-wide off-target effects underscoring therapeutic potential of this versatile and precise gene editing strategy.
UR - http://www.scopus.com/inward/record.url?scp=85093955574&partnerID=8YFLogxK
U2 - 10.1038/s41467-020-19136-7
DO - 10.1038/s41467-020-19136-7
M3 - Article
C2 - 33097693
SN - 2041-1723
VL - 11
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 5352
ER -